Endpoints News 生物医药· Elizabeth Cairns·· 2026-10-21AI 评分28
Eli Lilly 的 retatrutide 在睡眠呼吸暂停适应症上更接近上市
Lilly’s retatrutide creeps closer to market for sleep apnea
AI 导读
Eli Lilly 的三重激动剂 retatrutide 在睡眠呼吸暂停适应症上更接近上市。其肥胖适应症的上市预期为明年,公司也在推进该药用于睡眠呼吸暂停。
正文
Expectations for the launch of Eli Lilly’s triple agonist retatrutide in obesity, due next year, are at fever pitch. But the company is also lining …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news